Copenhagen and Oslo, 23rd March 2012, 2012-03-23 15:49 CET (GLOBE NEWSWIRE) -- Affitech A/S (NASDAQ OMX: AFFI) has changed the date for the release of its full year financial results from March 29th, 2012 to March 31st, 2012.
The updated financial calendar for 2012 is as follows:
16th March, 2012 Deadline for proposals for the Annual General Meeting, 2012
31st March, 2012 Financial Results 2011
27th April, 2012 Annual General Meeting
24th May, 2012 Interim financial report for 1st quarter 2012
30th August, 2012 Interim financial report for 2nd quarter 2012
22nd November, 2012 Interim financial report for 3rd quarter 2012
About Affitech
Affitech AS is a publicly traded (NASDAQ OMX Copenhagen) human therapeutic antibody company based in Copenhagen, Denmark with R&D facilities in Oslo, Norway. The company utilizes a range of proprietary antibody technologies for the discovery of fully human antibodies for application in oncology, inflammation and other disease areas. CBAS™ (Cell Based Antibody Selection) is Affitech’s premier discovery engine for the isolation of lead antibodies to cell surface molecules in situ. Several of the Company's proprietary product candidates were generated by CBAS™. Further information is available at www.affitech.com.
For more information please contact
Randi Krogsgaard, Director IR & Communications
Tel # +45 2320 1001, e-mail: ir@affitech.com
